CERO THERAPEUTICS HOLDINGS, INC.

CERO Therapeutics Holdings, Inc. trades under the ticker PBAX following the completed business combination between Phoenix Biotech Acquisition Corp and CERO Therapeutics, a clinical-stage biopharmaceutical company focused on immuno-oncology. Phoenix Biotech Acquisition Corp, sponsored by Phoenix Biotech Sponsor LLC, conducted its initial public offering in 2021, targeting the healthcare and life sciences sector. The December 2025 8-K filing reflects the combined company's ongoing public reporting obligations as a post-merger entity, with CERO Therapeutics advancing its chimeric engulfment receptor T-cell therapy platform for oncology indications. For complete filing history, sponsor profiles, and deal analytics on PBAX and the broader SPAC universe, sign up for full data access at SpacDesk.